Wrapping up 2024: Noteworthy events in medicines law and policy around the globe

Welcome to Medicines Law & Policy’s  end of the year blog, our highly biased annual overview of memorable medicines law and policy events. January At the...

The world needs a signal that multilateralism works: ML&P opening statement to the INB13,...

Thank you for the opportunity to make a brief statement. The negotiations for the Pandemic Agreement enter the final phase. We hope and wish for...

Covid-19 intellectual property pool gaining support

While drug and vaccine developers are working on tools to prevent and treat Covid- 19, here is a question the rest of us should...

The European Commission’s proposal for an EU wide compulsory licensing mechanism

In 2006 the European Generics Association was seeking clarification from the European Commission on whether generic versions of oseltamivir (Tamiflu) could be supplied to...

UN “Pact for the Future” intellectual property actions need revision to ensure innovation and...

UPDATE: From 22-23 September 2024, the Summit of the Future took place and adopted the Pact for the Future. The intellectual property paragraph of...

Wrapping up 2023 with some noteworthy medicines, law and policy developments

Welcome to our 2023 end-of-the-year blog, our annual and highly-biased run-through of notable access to medicines events of the year that is about to...

Dutch Health Care Institute Says No to Medicines Pirate

It seems the Dutch health care system and health care professionals are fed up with the abuse of the orphan medicines regulation, which is...

Gilead’s sofosbuvir patent in India – options for global access to new hepatitis C...

Earlier this month the US pharmaceutical company Gilead obtained a patent in India for sofosbuvir, part of a treatment of hepatitis C that became...

World Trade Organization Members Embark on Review of the TRIPS Agreement

The World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council will meet on 10-11 July. On the agenda is the review...

Something is going terribly wrong with the EU Compulsory Licensing Regulation

This week the European Parliament will vote on amendments to the Commission’s proposed regulation of the European Parliament and the Council on compulsory licensing...